Myriad Genetics
American genetic testing and precision medicine company offering molecular diagnostics for cancer, prenatal, mental health, and oncology applications.
Myriad Genetics Investor Relations – News ReleaseMyriad Genetics, Inc. is a publicly traded American genetic testing and precision medicine company headquartered in Salt Lake City, Utah, founded in 1991 by Peter Meldrum and Mark Skolnick and listed on NASDAQ under the ticker MYGN. The company develops and commercializes molecular tests that assess disease risk, guide treatment decisions, and enhance patient care across oncology, hereditary cancer risk, family planning, prenatal care, mental health, pharmacogenomics, and urology.
Key flagship products include BRACAnalysis CDx®, an FDA-approved companion diagnostic identifying germline BRCA1/2 mutations for targeted therapy eligibility; the MyRisk® hereditary cancer panel; and the GeneSight® pharmacogenomic test supporting mental health medication selection. The company operates across 46 global locations and employs between 1,000 and 5,000 professionals.
Myriad reported full-year 2024 revenue of $838 million, representing 11% year-over-year growth — its second consecutive year of double-digit revenue growth — with strong performance in Pharmacogenomics (14% growth), Prenatal testing (12% growth), and a Q4 GAAP gross margin of 71.7%. As of April 30, 2025, Sam Raha succeeded Paul J. Diaz as President and CEO.
Innovations in genomic diagnostics, pharmacogenomics, and AI-driven molecular testing are highly relevant to Myriad given its core business of translating genetic insights into clinical decision-making at scale.